MediPoint: Coronary Stents - Global Analysis and Market Forecasts
Summary
The global coronary stents market is a dynamic, double-digit market that is saturated with numerous players developing innovative technologies. Rapid advances in the field of interventional cardiology along with the development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. Coronary stents including bare metal, drug-eluting, covered and bioabsorbable stents can be used to treat coronary artery disease, and optimize outcomes.
Among the different types of stents, drug-eluting stents (DES) dominate the market and are considered to be the gold standard of treatment for coronary artery disease. The rising prevalence of disease and associated risk factors, especially in the emerging markets, and improved outcomes with stenting are expected to drive the adoption of coronary stents in the future. Emerging technologies such as the new generation of DES and bioabsorbable stents (BAS) represent the future of the coronary stent market. BAS offer several benefits, including no metal left behind, enhanced vessel healing, feasibility of future interventions and potentially reducing the need for prolonged dual antiplatelet therapy. With improvements in the design of BAS, they have the potential to become the standard of treatment for coronary artery disease in the future.
This report focuses on the global coronary stents market in the 10 major markets (10MM) (US, France, Germany, Italy, Spain, UK, Japan, China, India, and Brazil) for treating coronary artery disease. The global bare metal stents (BMS) and DES market is determined for the 10 countries covered in this report and provides insight into the competitive landscape, the marketed and pipeline products, the current and emerging players and market analysis of the different stent segments within the market. The report identifies the unmet needs in the market while providing an understanding of physicians’ perceptions and decision-making processes in using and evaluating the adoption of different types of coronary stents.
Highlights
Key Questions Answered
- What is the current and future coronary stents market outlook in the developed and emerging markets? What trends are affecting the global coronary stents market?
- Which are the key, high growth markets that stent manufacturers should expand into? What coronary stent segments are growing the fastest, and what are the top-selling stents in the category?
- Bare metal and drug-eluting stents have been on the market for many years; however, unmet needs still exist with respect to late and very late thrombosis and the need for prolonged dual anti-platelet therapy. How will emerging technologies such as DES with biodegradable polymer/polymer-free systems and BAS fulfill these unmet needs?
- What clinical factors and technical specifications influence a physician to use one type of coronary stent over another? What is physician perception and market outlook of BAS?
- What are the challenges and complications of BAS that have hindered widespread adoption?
• With developing the next-generation of coronary stents, what aspects of the stent technology are device manufacturers focused on optimizing? How will new entrants impact the coronary stents market?
Scope
- An overview of percutaneous coronary interventions, which includes clinical outcomes, diagnosis, and treatment using minimally invasive techniques.
- Annualized total coronary stents market revenue from 2011-2020 including adoption patterns.
- Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement considerations, and implications for the coronary stents market.
- Pipeline analysis: comprehensive list of products across different stages of development that would impact the coronary stents market with emerging trends and designs in development.
- Analysis of the current and future market competition in the global coronary stents market. Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
- “What Physicians Think” quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. In this report you will understand the perceptions of leading Interventional Cardiologists from around the world. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.
Table Of Contents
1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 18
1.2 List of Figures 26
2 Introduction 29
2.1 Catalyst 30
2.2 Related Reports 31
3 Industry Overview 32
3.1 Disease Overview 32
3.2 Clinical Outcomes 33
3.2.1 Treatment Guidelines 33
3.2.2 Treatment Modalities 34
3.3 Procedure Trends 48
3.3.1 United States 50
3.3.2 European Union 51
3.3.3 Asia-Pacific 53
3.3.4 Brazil 55
3.4 Market Access 56
3.4.1 Regulatory Process 57
3.4.2 Physician Decision-Making Process 63
3.4.3 Role of Group Purchasing Organizations 67
3.4.4 Lack of Clinical Data 70
3.4.5 Regional-Level Control 72
3.4.6 Cost Considerations 73
3.4.7 Reimbursement Trends 78
3.5 Regulatory Issues/Recalls 89
3.5.1 Regulatory Issues 89
3.5.2 Product Recalls 90
3.6 Mergers and Acquisitions/ Key Partnerships 90
3.6.1 Medtronic and Covidien 90
3.6.2 Arterial Remodeling Technologies and Terumo Corporation 91
3.6.3 MicroPort Scientific Corporation and Cordis Corporation 91
3.6.4 Alvimedica and CID 92
3.6.5 ITGI Medical and Vascular Solutions 92
3.6.6 Terumo Corporation and Onset Medical Corporation 93
3.6.7 Atrium Medical and Getinge Group 93
3.6.8 C.R. Bard and ClearStream Technologies 93
3.6.9 Biosensors International and Devax, CardioMind, and JW Medical Systems 94
3.6.10 CeloNova Biosciences and Nexeon MedSystems 95
3.6.11 Medtronic and Invatec 95
3.6.12 Micell Technologies and Maxcor Lifescience 96
3.6.13 Boston Scientific Corporation and Guidant Corporation 96
3.6.14 Abbott Vascular and Guidant Corporation 96
3.6.15 Kaneka Corporation and Fujisawa Pharmaceuticals 97
3.7 Economic Impact of Coronary Artery Disease 97
3.7.1 United States 98
3.7.2 European Union 100
3.7.3 Asia-Pacific 101
3.7.4 Brazil 102
3.8 Treatment Costs for Coronary Artery Disease 103
4 Unmet Needs 105
4.1 Need for Better Clinical Outcomes in Specific Lesions 105
4.1.1 Chronic Total Occlusions 105
4.1.2 Small-Vessel Coronary Lesions 106
4.1.3 Heavily-Calcified and Uncrossable/Undilatable Lesions 107
4.1.4 Bifurcation Lesions 107
4.1.5 Saphenous Vein Graft Intervention 108
4.2 Eliminating Mechanisms of Failure With Balloon Angioplasty 109
4.3 Late Myocardial Infarction After Stenting 109
4.4 Eliminating the Permanent Polymer 110
4.5 In-Stent Restenosis 111
4.6 Stent-In-Stent Procedures 113
4.7 Prolonged Dual Antiplatelet Therapy 114
4.8 Lack of Homogenous Drug Distribution 115
4.9 Delayed Stent Endothelialization 115
4.10 Negative Vessel Remodeling 116
4.11 Need for Effective Therapy for Specific Patient Populations 116
4.12 Addressing the Complications of Coronary Artery Bypass Grafting 117
5 Market Opportunity Analysis 118
5.1 Improve Stent Design/Platform 118
5.1.1 Stent Coating Technology 119
5.1.2 Bioabsorbable Stent Technology 121
5.1.3 Antiproliferative Drug and Elution Kinetics 122
5.2 Hybrid Stent Systems 124
5.3 Effective Therapies for Challenging Coronary Indications 125
5.3.1 Chronic Total Occlusions 125
5.3.2 Small-Vessel Disease 125
5.3.3 Bifurcation Lesions 126
5.3.4 Diffuse Atherosclerotic Disease 127
5.3.5 Saphenous Vein Graft Intervention 127
5.3.6 Acute Myocardial Infarction 127
5.4 Target Challenging Patient Populations 128
5.5 Emerging Markets 129
6 Market Drivers, Barriers, and Substitutes 130
6.1 Market Drivers 130
6.1.1 Rising Prevalence of Disease 131
6.1.2 Viable Treatment for Challenging Coronary Indications 132
6.1.3 Innovations in Stent Technology 133
6.1.4 Development of Bioabsorbable Stents 135
6.1.5 Reduce the Need for Prolonged Dual Antiplatelet Therapy 137
6.1.6 Potential Cost Savings 138
6.1.7 Use of Imaging Modalities for Accurate Stent Placement 139
6.1.8 Adoption of Stents in the Emerging Markets 139
6.1.9 Launch of Bioabsorbable Stents in US and Japan 140
6.2 Market Barriers 140
6.2.1 Concerns Regarding Overstenting 140
6.2.2 Post-ProceduraI Complications of Drug-Eluting Stenting 141
6.2.3 Risk of Perioperative Adverse Cardiac Events Post-Stenting 141
6.2.4 Slow Adoption of Bioabsorbable Stents 142
6.2.5 Lack of Reimbursement 147
6.2.6 Healthcare Cost-Cutting and Reimbursement 148
6.2.7 Availability of Venture Capital 149
6.2.8 Medical Device Excise Tax 150
6.3 Market Substitutes 150
6.3.1 Drug-Eluting Balloons 150
6.3.2 Liquid Drug Delivery Catheter 151
7 Competitive Assessment 153
7.1 Overview 153
7.2 Trends in Coronary Stent Technology Development 154
7.2.1 Development of Bare Metal Stents 154
7.2.2 Development of Drug-Eluting Stents 156
7.2.3 Development of Bioabsorbable Stents 159
7.2.4 Development of Covered Stents 160
7.2.5 Coronary Stent Technology SWOT Analysis 161
7.3 Global Company Market Share 162
7.3.1 Bare Metal Stent Market Share 162
7.3.2 Drug-Eluting Stent Market Share 163
7.4 Regional Company Market Share 164
7.4.1 US Market Share 164
7.4.2 EU Market Share 166
7.4.3 APAC Market Share 168
7.4.4 Brazil Market Share 170
8 Pipeline Products 173
8.1 Overview 173
8.2 Pipeline by Stage of Development 173
8.3 Pipeline Product Profiles 176
8.3.1 Bioabsorbable Stents 176
8.3.2 Other Types of Vascular Stents 187
9 Clinical Trial Analysis 193
9.1 Overview 193
9.2 Clinical Trials to Watch 193
9.2.1 Evaluating the Latest and New Generation of Drug-Eluting Stents 193
9.2.2 Bioabsorbable Stent Clinical Trials 195
9.2.3 Evaluating Stenting in Challenging Coronary Indications/Patient Populations 199
9.2.4 Targeting Patient Populations in the APAC Region 201
10 Current and Future Players 203
10.1 Overview 203
10.2 Trends in Corporate Strategy 203
10.3 Company Profiles 206
10.3.1 Abbott Vascular 206
10.3.2 Boston Scientific Corporation 212
10.3.3 Medtronic 219
10.3.4 Alvimedica 225
10.3.5 Amaranth Medical 229
10.3.6 amg International 232
10.3.7 Arterial Remodeling Technologies 236
10.3.8 B. Braun 239
10.3.9 Balton 242
10.3.10 Biosensors International 247
10.3.11 Biotronik 251
10.3.12 Blue Medical 256
10.3.13 Cardionovum 260
10.3.14 C.R. Bard 264
10.3.15 Elixir Medical Corporation 268
10.3.16 eucatech AG 273
10.3.17 Hexacath 277
10.3.18 IRAMED 280
10.3.19 JW Medical Systems 283
10.3.20 Kyoto Medical Planning 286
10.3.21 Lepu Medical Technology 290
10.3.22 MicroPort Scientific Corporation 294
10.3.23 Minvasys 298
10.3.24 MIV Therapeutics 302
10.3.25 Opto Circuits 306
10.3.26 OrbusNeich Medical 310
10.3.27 Relisys Medical Devices 314
10.3.28 REVA Medical 318
10.3.29 Sahajanand Medical Technologies 321
10.3.30 STENTYS 325
10.3.31 Terumo Corporation 329
10.3.32 Translumina 333
10.3.33 Vascular Concepts 337
10.3.34 Other Companies 341
11 Market Outlook 353
11.1 By Market Segment 353
11.1.1 Overview 353
11.1.2 Drug-Eluting Stent Market 354
11.1.3 Bare Metal Stent Market 356
11.1.4 Emerging Stent Technologies 357
11.2 By Indication 359
11.3 By Geography 360
11.3.1 Overview 360
11.3.2 United States 363
11.3.3 5EU 366
11.3.4 Asia-Pacific 379
11.3.5 Brazil 390
12 Appendix 393
12.1 Bibliography 393
12.2 Abbreviations 417
12.3 Report Methodology 424
12.3.1 Overview 424
12.3.2 Coverage 424
12.3.3 Secondary Research 424
12.4 Physicians and Specialists Included in This Study 426
12.4.1 Praveen Chandra, MD, DM, FESC, FSCAI, FAPSCI 426
12.4.2 Bernado Cortese, MD, FESC 426
12.4.3 Ricardo A. Costa, MD 426
12.4.4 Thomas Cuisset, MD, PhD, FESC 426
12.4.5 Nobuyuki Komiyama, MD, PhD, FACC, FJCC 426
12.4.6 Roger J. Laham, MD 426
12.4.7 Mark W. Mewissen, MD 426
12.4.8 Gary S. Mintz, MD 426
12.4.9 Tudor C. Poerner, MD 427
12.4.10 David Ramsdale, MD, PhD 427
12.4.11 Gregory A. Sgueglia, MD, PhD 427
12.4.12 Madhukar Shahi, MD 427
12.4.13 Takehiro Yamashita, MD, PhD, FACC 427
12.5 Primary Research 428
12.5.1 Primary Research - Key Opinion Leader Interviews 428
12.5.2 Primary Research Interviews- Physician and Industry Participants 428
12.5.3 Physican Survey 429
12.5.4 Expert Panel Validation 430
12.6 Forecasting Methodology 431
12.7 About the Authors 433
12.7.1 Analysts 433
12.7.2 Global Head of Healthcare 434
12.8 About MediPoint 435
12.9 About GlobalData 435
12.10 Disclaimer 435
List Of Tables
1.1 List of Tables
Table 1: ACCF/AHA Treatment Guidelines to Improve the Symptoms of CAD* 34
Table 2: Types of CABG 37
Table 3: Complications of CABG 38
Table 4: Drugs Incorporated Into DES 41
Table 5: Types of Lesions Treated Using Atherectomy 45
Table 6: GPOs in the US and EU 68
Table 7: Medicare National Average of Inpatient Hospital Payment for CAD Therapeutic Procedures, 2013-2015 79
Table 8: Reimbursement Classification of Medical Devices in Japan 86
Table 9: Direct and Indirect Healthcare Costs of CAD 98
Table 10: Healthcare Expenditures ($bn, 2008$) for CAD in the US, 2011-2020 99
Table 11: Healthcare Expenditures ($bn) for CAD in the 5EU, 2006 101
Table 12: US Mean Hospital Costs* ($US) for Cardiac Revascularization Procedures, 2011-2020 104
Table 13: Coronary Stent Technology SWOT Analysis, 2014 161
Table 14: Global Coronary Stent Pipeline Products, 2014 175
Table 15: ART18Z SWOT Analysis, 2014 177
Table 16: DREAMS SWOT Analysis, 2014 178
Table 17: Fantom SWOT Analysis, 2014 179
Table 18: Fortitude SWOT Analysis, 2014 180
Table 19: Ideal BioStent SWOT Analysis, 2014 181
Table 20: Igaki-Tamai Stent SWOT Analysis, 2014 183
Table 21: ON-AVS SWOT Analysis, 2014 184
Table 22: Other Companies Developing BAS, 2014 187
Table 23: FOCUS np Eluting Stent SWOT Analysis, 2014 188
Table 24: STENTYS Sirolimus-Eluting Stent SWOT Analysis, 2014 189
Table 25: Svelte Drug-Eluting Stent SWOT Analysis, 2014 191
Table 26: Clinical Trials Evaluating the Latest and New Generation of DES, 2014 194
Table 27: Clinical Trials Evaluating Stenting in Challenging CAD Indications/Patient Populations, 2014 200
Table 28: Clinical Trials Evaluating Coronary Stenting in APAC Patient Populations, 2014 202
Table 29: Abbott Vascular Company Profile 206
Table 30: Abbott Vascular Coronary Stent Marketed Products 208
Table 31: Abbott Vascular Coronary Stent Product Portfolio SWOT Analysis, 2014 211
Table 32: Abbott Vascular SWOT Analysis, 2014 212
Table 33: Boston Scientific Corporation Company Profile 213
Table 34: Boston Scientific Coronary Stent Marketed Products 215
Table 35: Boston Scientific Coronary Stent Product Portfolio SWOT Analysis, 2014 218
Table 36: Boston Scientific Corporation SWOT Analysis, 2014 219
Table 37: Medtronic Company Profile 220
Table 38: Medtronic Coronary Stent Marketed Products 222
Table 39: Medtronic Coronary Stent Product Portfolio SWOT Analysis, 2014 224
Table 40: Medtronic SWOT Analysis, 2014 225
Table 41: Alvimedica Company Profile 226
Table 42: Alvimedica Coronary Stent Marketed Products 227
Table 43: Alvimedica Coronary Stent Product Portfolio SWOT Analysis, 2014 228
Table 44: Alvimedica SWOT Analysis, 2014 229
Table 45: Amaranth Medical Company Profile 230
Table 46: Amaranth Medical Coronary Stent Pipeline Product 230
Table 47: Amaranth Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 231
Table 48: Amaranth Medical SWOT Analysis, 2014 231
Table 49: amg International Company Profile 232
Table 50: amg International Coronary Stent Marketed Products 234
Table 51: amg International Coronary Stent Product Portfolio SWOT Analysis, 2014 235
Table 52: amg International SWOT Analysis, 2014 236
Table 53: Arterial Remodeling Technologies Company Profile 237
Table 54: Arterial Remodeling Technologies Coronary Stent Pipeline Product 237
Table 55: Arterial Remodeling Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014 238
Table 56: Arterial Remodeling Technologies SWOT Analysis, 2014 238
Table 57: B. Braun Company Profile 239
Table 58: B. Braun Coronary Stent Marketed Products 240
Table 59: B. Braun Coronary Stent Product Portfolio SWOT Analysis, 2014 241
Table 60: B. Braun SWOT Analysis, 2014 242
Table 61: Balton Company Profile 243
Table 62: Balton Coronary Stent Marketed Products 244
Table 63: BALTON Coronary Stent Product Portfolio SWOT Analysis, 2014 246
Table 64: Balton SWOT Analysis, 2014 246
Table 65: Biosensors International Company Profile 247
Table 66: Biosensors International Coronary Stent Marketed Products 249
Table 67: Biosensors International Coronary Stent Product Portfolio SWOT Analysis, 2014 250
Table 68: Biosensors International SWOT Analysis, 2014 251
Table 69: Biotronik Company Profile 252
Table 70: Biotronik Coronary Stent Marketed and Pipeline Products 253
Table 71: Biotronik Coronary Stent Product Portfolio SWOT Analysis, 2014 255
Table 72: Biotronik SWOT Analysis, 2014 256
Table 73: Blue Medical Company Profile 257
Table 74: Blue Medical Coronary Stent Marketed Products 258
Table 75: Blue Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 259
Table 76: Blue Medical SWOT Analysis, 2014 260
Table 77: Cardionovum Company Profile 261
Table 78: Cardionovum Coronary Stent Marketed and Pipeline Products 262
Table 79: Cardionovum Coronary Stent Product Portfolio SWOT Analysis, 2014 263
Table 80: Cardionovum SWOT Analysis, 2014 264
Table 81: C.R. Bard Company Profile 265
Table 82: ClearStream Technologies Coronary Stent Marketed Products 266
Table 83: C.R. Bard Coronary Stent Product Portfolio SWOT Analysis, 2014 267
Table 84: C.R. Bard SWOT Analysis, 2014 268
Table 85: Elixir Medical Corporation Company Profile 269
Table 86: Elixir Medical Corporation Coronary Stent Marketed Products 270
Table 87: Elixir Medical Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014 272
Table 88: Elixir Medical Corporation SWOT Analysis, 2014 273
Table 89: eucatech Profile 274
Table 90: eucatech Coronary Stent Marketed Products 275
Table 91: eucatech Coronary Stent Product Portfolio SWOT Analysis, 2014 276
Table 92: eucatech SWOT Analysis, 2014 277
Table 93: Hexacath Company Profile 278
Table 94: Hexacath Coronary Stent Marketed Products 279
Table 95: Hexacath Coronary Stent Product Portfolio SWOT Analysis, 2014 279
Table 96: Hexacath SWOT Analysis, 2014 280
Table 97: IRAMED Company Profile 280
Table 98: IRAMED Coronary Stent Marketed Products 281
Table 99: IRAMED Coronary Stent Product Portfolio SWOT Analysis, 2014 282
Table 100: IRAMED SWOT Analysis, 2014 283
Table 101: JW Medical Systems Company Profile 284
Table 102: JW Medical Systems Coronary Stent Marketed Product 284
Table 103: JW Medical Systems’ Coronary Stent Product Portfolio SWOT Analysis, 2014 285
Table 104: JW Medical Systems SWOT Analysis, 2014 286
Table 105: Kyoto Medical Planning Company Profile 287
Table 106: Kyoto Medical Planning Coronary Stent Pipeline Product 288
Table 107: Kyoto Medical Planning Coronary Stent Product Portfolio SWOT Analysis, 2014 289
Table 108: Kyoto Medical Planning SWOT Analysis, 2014 289
Table 109: Lepu Medical Technology Company Profile 290
Table 110: Lepu Medical Technology Coronary Stent Marketed and Pipeline Products 292
Table 111: Lepu Medical Technology Coronary Stent Product Portfolio SWOT Analysis, 2014 293
Table 112: Lepu Medical Technology SWOT Analysis, 2014 294
Table 113: MicroPort Scientific Corporation Company Profile 295
Table 114: MicroPort Scientific Corporation Coronary Stent Marketed Products 296
Table 115: MicroPort Scientific Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014 297
Table 116: MicroPort Scientific Corporation SWOT Analysis, 2014 298
Table 117: Minvasys Company Profile 299
Table 118: Minvasys Coronary Stent Marketed and Pipeline Products 300
Table 119: Minvasys Coronary Stent Product Portfolio SWOT Analysis, 2014 301
Table 120: Minvasys SWOT Analysis, 2014 302
Table 121: MIV Therapeutics Company Profile 303
Table 122: MIV Therapeutics Coronary Stent Marketed Products 304
Table 123: MIV Therapeutics Coronary Stent Product Portfolio SWOT Analysis, 2014 305
Table 124: MIV Therapeutics SWOT Analysis, 2014 306
Table 125: Opto Circuits Company Profile 307
Table 126: Opto Circuits Coronary Stent Marketed Products 308
Table 127: Opto Circuits Coronary Stent Product Portfolio SWOT Analysis, 2014 309
Table 128: Opto Circuits SWOT Analysis, 2014 310
Table 129: OrbusNeich Medical Company Profile 311
Table 130: OrbusNeich Medical Coronary Stent Marketed and Pipeline Products 312
Table 131: OrbusNeich Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 313
Table 132: OrbusNeich Medical SWOT Analysis, 2014 314
Table 133: Relisys Medical Devices Company Profile 315
Table 134: Relisys Medical Devices Coronary Stent Marketed Products 316
Table 135: Relisys Medical Devices Coronary Stent Product Portfolio SWOT Analysis, 2014 317
Table 136: Relisys Medical Devices SWOT Analysis, 2014 318
Table 137: REVA Medical Company Profile 319
Table 138: REVA Medical Coronary Stent Pipeline Product 319
Table 139: REVA Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 320
Table 140: REVA Medical SWOT Analysis, 2014 321
Table 141: Sahajanand Medical Technologies Company Profile 322
Table 142: Sahajanand Medical Technologies Coronary Stent Marketed and Pipeline Products 323
Table 143: Sahajanand Medical Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014 324
Table 144: Sahajanand Medical Technologies SWOT Analysis, 2014 325
Table 145: STENTYS Company Profile 326
Table 146: STENTYS Coronary Stent Marketed and Pipeline Products 327
Table 147: STENTYS Coronary Stent Product Portfolio SWOT Analysis, 2014 328
Table 148: STENTYS SWOT Analysis, 2014 329
Table 149: Terumo Corporation Company Profile 330
Table 150: Terumo Corporation Coronary Stent Marketed and Pipeline Products 331
Table 151: Terumo Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014 332
Table 152: Terumo Corporation SWOT Analysis, 2014 333
Table 153: Translumina Company Profile 334
Table 154: Translumina Coronary Stent Marketed Products 335
Table 155: Translumina Coronary Stent Product Portfolio SWOT Analysis, 2014 336
Table 156: Translumina SWOT Analysis, 2014 336
Table 157: Vascular Concepts Company Profile 337
Table 158: Vascular Concepts Coronary Stent Marketed Products 338
Table 159: Vascular Concepts Coronary Stent Product Portfolio SWOT Analysis, 2014 339
Table 160: Vascular Concepts SWOT Analysis, 2014 340
Table 161: Other Companies in the Coronary Stent Market, North America, 2014 341
Table 162: Other Companies in the Coronary Stent Market, EU, 2014 346
Table 163: Other Companies in the Coronary Stent Market, APAC, 2014 349
Table 164: Other Companies in the Coronary Stent Market, South Africa and South America, 2014 352
Table 165: Global Coronary Stent Sales ($m) Forecast, by Segment, 2011-2020 353
Table 166: Global DES Sales ($m) Forecast, 2011-2020 354
Table 167: Global BMS Sales ($m) Forecast, 2011-2020 356
Table 168: Coronary Stents Market Sales ($m) Forecast for the United States, 2011-2020 363
Table 169: EU Coronary Stent Sales ($m) Forecast, by Segment, 2011-2020 366
Table 170: Coronary Stents Market Sales ($m) Forecast for France, 2011-2020 368
Table 171: Coronary Stents Market Sales ($m) Forecast for Germany, 2011-2020 370
Table 172: Coronary Stents Market Sales ($m) Forecast for Italy, 2011-2020 373
Table 173: Coronary Stents Market Sales ($m) Forecast for Spain, 2011-2020 375
Table 174: Coronary Stents Market Sales ($m) Forecast for the UK, 2011-2020 377
Table 175: APAC Coronary Stent Sales ($m) Forecast, by Segment, 2011-2020 380
Table 176: Coronary Stents Market Sales ($m) Forecast for Japan, 2011-2020 381
Table 177: Coronary Stents Market Sales ($m) Forecast for China, 2011-2020 384
Table 178: Coronary Stents Market Sales ($m) Forecast for India, 2011-2020 387
Table 179: Coronary Stents Market Sales ($m) Forecast for Brazil, 2011-2020 390
Table 180: Primary Research Interviews Completed 429
Table 181: Physicians Surveyed, By Country 430
List Of Figures
1.2 List of Figures
Figure 1: Pathophysiology of CAD 32
Figure 2: CAD Treatment Modalities 35
Figure 3: Percentage of Patients with CAD Who Receive Each Therapy Option Only, Global, 2012 and 2019 (N=58) 36
Figure 4: Percentage of Patients with CAD Who Receive Each Type of PCI Only, Global, 2012 and 2019 (N=58) 39
Figure 5: Types of Stents Used to Treat CAD 40
Figure 6: Example of a BMS 41
Figure 7: Example of a DEB 44
Figure 8: Types of Atherectomy 46
Figure 9: Global Coronary Stenting Procedure Volume, 2011-2020 49
Figure 10: US Coronary Stenting Procedure Volume, 2011-2020 50
Figure 11: 5EU Coronary Stenting Procedure Volume, 2011-2020 52
Figure 12: APAC Coronary Stenting Procedure Volume, 2011-2020 54
Figure 13: Brazil Coronary Stenting Procedure Volume, 2011-2020 56
Figure 14: Healthcare Expenditures ($bn, 2008$) for CAD in the US, 2011-2020 99
Figure 15: US Mean Hospital Costs* ($US) for Cardiac Revascularization Procedures, 2011-2020 104
Figure 16: Percentage of CAD Patients with ISR, Global, 2012 and 2018 (N=58) 112
Figure 17: Percentage of CAD Patients Who Receive Stent-In-Stent Procedures, Global, 2012 and 2018 (N=58) 114
Figure 18: Interventional Cardiologists’ Ranking of the Importance of Each Therapy Attribute in Adopting Stents for the Treatment of CAD, Global, 2013 (N=101) 119
Figure 19: Global Coronary Stents Market Value Share (%), 2013 and 2020 154
Figure 20: Global BMS Company Market Share (%), 2013 163
Figure 21: Global DES Company Market Share (%), 2013 164
Figure 22: US Market Share for BMS (%), 2013 165
Figure 23: US Market Share for DES (%), 2013 166
Figure 24: EU Market Share for BMS (%), 2013 167
Figure 25: EU Market Share for DES (%), 2013 168
Figure 26: APAC Market Share for BMS (%), 2013 169
Figure 27: APAC Market Share for DES (%), 2013 170
Figure 28: Brazil Market Share for BMS (%), 2013 171
Figure 29: Brazil Market Share for DES (%), 2013 172
Figure 30: Global Coronary Stent Pipeline Products by Stage of Development, 2014 174
Figure 31: Global Coronary Stents Market Revenue ($m), 2011-2020 354
Figure 32: Global DES Market Revenue ($m), 2011-2020 355
Figure 33: Global BMS Market Revenue ($m), 2011-2020 357
Figure 34: Percentage of Patients (%) Treated with Each Type of Coronary Stent Only, Global, 2013 and 2020 (N=101) 359
Figure 35: Percentage of Patients (%) Treated with Coronary Stents for Each Indication, Global, 2013 and 2020 (N=101) 360
Figure 36: Global Coronary Stents Market Revenue ($bn), 2013 and 2020 362
Figure 37: US Sales ($m) Forecast for Coronary Stents, 2011-2020 364
Figure 38: EU Sales ($m) Forecast for Coronary Stents, 2011-2020 367
Figure 39: French Sales ($m) Forecast for Coronary Stents, 2011-2020 369
Figure 40: German Sales ($m) Forecast for Coronary Stents, 2011-2020 371
Figure 41: Italian Sales ($m) Forecast for Coronary Stents, 2011-2020 373
Figure 42: Spanish Sales ($m) Forecast for Coronary Stents, 2011-2020 375
Figure 43: UK Sales ($m) Forecast for Coronary Stents, 2011-2020 378
Figure 44: APAC Sales ($m) Forecast for Coronary Stents, 2011-2020 380
Figure 45: Japanese Sales ($m) Forecast for Coronary Stents, 2011-2020 382
Figure 46: Chinese Sales ($m) Forecast for Coronary Stents, 2011-2020 386
Figure 47: Indian Sales ($m) Forecast for Coronary Stents, 2011-2020 388
Figure 48: Brazilian Sales ($m) Forecast for Coronary Stents, 2011-2020 391
